Mavrilimumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Mavrilimumab
- Accession Number
- DB12534
- Description
Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- CAM-3001
- Mavrilimumab
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Mavrilimumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Mavrilimumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mavrilimumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Mavrilimumab. Ansuvimab The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Mavrilimumab. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Mavrilimumab. Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mavrilimumab. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Mavrilimumab. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Mavrilimumab. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 1158JD1P9A
- CAS number
- 1085337-57-0
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911343
- Wikipedia
- Mavrilimumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID 19 / Pneumonia / SARS-CoV 2 1 2 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Pneumonia 1 2 Active Not Recruiting Treatment Giant Cell Arteritis (GCA) 1 2 Completed Treatment Rheumatoid Arthritis 3 2 Not Yet Recruiting Treatment Acute Respiratory Failure / ARDS, Human / Coronavirus Disease 2019 (COVID‑19) / Viral Pneumonia 1 2 Not Yet Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID 19 / Pneumonia / SARS-CoV 2 1 2 Terminated Treatment Rheumatoid Arthritis 1 2, 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 1 1 Completed Treatment Healthy Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 20, 2016 22:45 / Updated on February 21, 2021 18:53